Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a bullish outlook on Roivant Sciences Ltd. (NASDAQ:ROIV) on February 6, revising ...

Roivant Sciences beat estimated earnings by 29.41%, reporting an EPS of $-0.24 versus an estimate of $-0.34. Revenue was down $7.02 million from the same period last year. Last quarter the company ...

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript February 6, 2026 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $-0.00038, expectations were $-0.27. Operator: ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.13 per share a year ago. These ...

Roivant Sciences is upgraded to Buy after strong Phase 2 BEACON data for brepocitinib in cutaneous sarcoidosis, highlighting blockbuster potential. Brepocitinib's once-daily oral profile and robust ...

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...